Ellinwood E H, Nikaido A M, Gupta S K, Heatherly D G, Nishita J K
Duke University Medical Center, Durham, North Carolina.
J Pharmacol Exp Ther. 1990 Dec;255(3):1133-9.
Two experiments were designed to examine the pharmacokinetic-pharmacodynamic relationship for the central nervous system and peripheral effects of atropine. According to a random Latin square design, healthy young male volunteers were given i.m. injections containing single doses of placebo or 0.5, 1.0, 2.0 or 4.0 mg of atropine. The central nervous system tests included wheel tracking, a coordination task, and digit symbol substitution, a memory-psychomotor speed task; the physiological variable was heart rate. The pharmacokinetics of atropine were best described by a two-compartment model with very rapid first order absorption. Changes in plasma atropine levels and heart rate closely overlapped for all four doses throughout most of the time course. In contrast, the differential time course of changes in atropine levels and behavioral impairment indicates that pharmacokinetics is not the primary rate-limiting mechanism for the central nervous system effects of atropine. Alternative explanations are discussed, including differential atropine effects on peripheral M2 receptors mediating a heart rate effect and on CNS M1 receptors mediating the memory-psychomotor effect.
设计了两项实验来研究阿托品对中枢神经系统和外周效应的药代动力学-药效学关系。根据随机拉丁方设计,给健康年轻男性志愿者肌内注射含单剂量安慰剂或0.5、1.0、2.0或4.0毫克阿托品的注射液。中枢神经系统测试包括轮替试验(一项协调性任务)和数字符号替换试验(一项记忆-心理运动速度任务);生理变量为心率。阿托品的药代动力学最好用具有非常快速一级吸收的二室模型来描述。在大部分时间进程中,所有四个剂量的血浆阿托品水平变化和心率变化密切重叠。相比之下,阿托品水平变化和行为损害的不同时间进程表明,药代动力学不是阿托品对中枢神经系统效应的主要限速机制。文中讨论了其他解释,包括阿托品对介导心率效应的外周M2受体和介导记忆-心理运动效应的中枢神经系统M1受体的不同作用。